CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.150

+2.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brett Nelson who wrote (101)	1/24/1998 5:18:00 PM
From: Harold Engstrom	Read Replies (1) of 668

I've heard a royalty figure for OP-1 from Stryker upon approval of roughly $80MM per year. That number could be totally bogus, but if true it would support a much higher stock price. If OP-1 proceeds on other indications like renal failure, then milestone payments and royalties from Biogen would pile up as well. So, I think a significantly higher price would be appropriate if these scenarios play out.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next